Successful treatment of thrombotic thrombocytopenic purpura (TTP) with Rituximab;Erfolgreiche behandlung einer thrombotisch thrombozytopenischen purpura mit rituximab
IMMUNOGLOBULIN;
PREDNISONE;
RITUXIMAB;
VON WILLEBRAND FACTOR CLEAVING PROTEINASE;
ABSENCE OF SIDE EFFECTS;
ADOLESCENT;
ANTIBODY DETECTION;
ARTICLE;
CASE REPORT;
DRUG MEGADOSE;
DRUG TREATMENT FAILURE;
FEMALE;
HUMAN;
MEDICAL ASSESSMENT;
PLASMAPHERESIS;
THROMBOCYTE COUNT;
THROMBOTIC THROMBOCYTOPENIC PURPURA;
Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias
Allford SL, Hunt BJ, Rose P, Machin SJ. Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias. Br J Haematol 2003; 120(4): 556-73.
Addition of rituximab to standard therapy improves response rate and progression-free survival in relapsed or refractory thrombotic thrombocytopenic purpura and autoimmune haemolytic anaemia
Heidel F, Lipka DB, von Auer Ch, Huber Ch, Scharrer I, Hess G. Addition of rituximab to standard therapy improves response rate and progression-free survival in relapsed or refractory thrombotic thrombocytopenic purpura and autoimmune haemolytic anaemia. Thromb Haemost 2007; 97/2: 228-33.
Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with the reduction in IgG antibodies to ADAMTS13
Scully M, Cohen H, Cavenagh J, et al. Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with the reduction in IgG antibodies to ADAMTS13 Br J Haematol 2007; 136(3): 451-61.
A dramatic response to rituximab in a patient with resistant thrombotic thrombocytopenic purpura (TTP) who developed acute stroke
Ozdogu H, Boga C, Kizilkilic E, Yeral M, Kozanoglu I, Karatas M. A dramatic response to rituximab in a patient with resistant thrombotic thrombocytopenic purpura (TTP) who developed acute stroke J Thromb Thrombolysis 2007; 23: 147-50.
